A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab

Megna, Matteo; Battista, Teresa; Potestio, Luca; Ruggiero, Angelo; Ventura, Virginia; Fabbrocini, Gabriella; Picone, Vincenzo

doi:10.1111/jocd.15543

Cited by 22 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the introduction of new drugs selectively targeting pathogenetic mechanisms has led to the development of selective drugs. 119–121 …”

Section: Discussionmentioning

confidence: 99%

JAK Inhibitors in Psoriatic Disease

Megna,

Potestio,

Ruggiero

et al. 2023

CCID

Self Cite

View full text Add to dashboard Cite

Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory condition, recognized under the term Psoriatic Disease (PsD). PsD has several extracutaneous manifestations, such as inflammatory articular and entheseal involvement, leading to psoriatic arthritis (PsA), and the less frequent intestinal and ocular manifestations with colitis/inflammatory bowel disease and uveitis, respectively. There have also been several reports of an increased frequency of comorbidities such as hypertension, diabetes, dyslipidemia, obesity, metabolic syndrome and cardiovascular manifestations during the course of PsD. The link between psoriasis and related comorbidities is considered a long-term disease sequela, often characterized by an unhealthy lifestyle and a consequence of systemic inflammation; hence, psoriasis requires adequate and prompt treatment, with the aim of controlling not only cutaneous manifestations but also extracutaneous manifestations and systemic inflammation. Pharmacological strategies for PsD have significantly increased over recent years. Recently, the targeted synthetic DMARDs, Janus kinase (JAK) inhibitors, tofacitinib and upadacitinib, were added to the therapeutic armamentarium for treating PsA, and deucravacitinib for psoriasis. These oral agents act directly on inflammatory mechanisms underlining the disease, as antagonists of the intracellular JAK signal pathway and, by STAT phosphorylation, inhibit gene proinflammatory cytokine transcription. JAK inhibitors represent a recent additional treatment strategy for PsD management and, among these, tofacitinib and upadacitinib have recently been approved for PsA, and deucravacitinib for psoriasis. In this review we describe ongoing and recent phase II and III randomized controlled trials (RCTs) evaluating the efficacy and safety of investigational JAK inhibitors in psoriasis and PsA.

show abstract

“…Recently, the introduction of new drugs selectively targeting pathogenetic mechanisms has led to the development of selective drugs. 119–121 …”

Section: Discussionmentioning

confidence: 99%

JAK Inhibitors in Psoriatic Disease

Megna,

Potestio,

Ruggiero

et al. 2023

CCID

Self Cite

View full text Add to dashboard Cite

show abstract

“…These include topical treatments (creams and ointments) which may be used for the mild form of the disease, phototherapy (exposure to ultraviolet light), conventional systemic medications (cyclosporin, methotrexate, acitretin, and fumarates), small molecules, and biologic therapies which are used for moderate-to-severe forms [ 10 , 11 , 12 , 13 ]. In particular, the introduction of biologic drugs specifically targeting interleukins (IL) 23 and 17 and tumor necrosis factor-alpha (TNFα), involved in psoriasis pathogenesis, revolutionized the management of the disease, showing promising results in terms of effectiveness and safety [ 14 , 15 , 16 ]. Globally, treatment plans are tailored to everyone’s specific needs, taking into account the severity of the disease, its impact on a patient’s quality of life, and the comorbidities [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

et al. 2023

Self Cite

View full text Add to dashboard Cite

COVID-19 vaccination was the main measure to overcome the pandemic. As with other drugs and vaccines, mild to moderate adverse events have been reported following vaccination. In addition, several cutaneous reactions have been described. In particular, there are several reports investigating de novo psoriasis or the exacerbation of psoriasis following COVID-19 vaccination. However, data on the possible pathogenetic mechanisms as well as comprehensive manuscripts on the topic are scant. Thus, the aim of our manuscript was to perform a review of the current literature on post-COVID-19 vaccination exacerbations and new-onset psoriasis in order to offer a wide perspective on this area and to point out possible pathogenetic mechanisms. Research on the current literature was performed following PRISMA guidelines. In total, 49 studies involving 134 patients developing new-onset psoriasis (n = 27, 20.1%) or psoriasis exacerbation (n = 107, 79.9%) were collected. Although cases of de novo psoriasis or a worsening of psoriasis have been reported following vaccination, all of the cases have been successfully treated while overall benefit–risk profile of COVID-19 vaccination does not justify vaccine hesitancy due to the risk of psoriasis being developed or worsening. Certainly, further studies are needed to identify possible pathogenetic mechanisms in order to identify “at-risk” patients. Finally, vaccination should not be discouraged.

show abstract

“…It has a safety profile consistent with other biologics, apart from an increased incidence of oropharyngeal candidiasis [ 22 ]. Real-world data also supports the efficacy of bimekizumab for plaque psoriasis [ 23 ] and there is case evidence for its use in erythrodermic psoriasis [ 24 ].…”

Section: Introductionmentioning

confidence: 98%

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Burshtein,

Shah,

Zakria

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for treating moderate to severe psoriasis. Limited guidelines exist for incorporating this drug into clinical practice. The purpose of this study was for a panel of experts in psoriasis management to synthesize current literature and provide consensus statements with guidance on use of bimekizumab. Methods A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the use of bimekizumab for moderate to severe psoriasis and psoriatic arthritis. A panel of nine dermatologists with significant expertise in treatment of psoriasis gathered to review the articles and create consensus statements on this new medication. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using Strength of Recommendation Taxonomy criteria. Results The literature search produced 102 articles that met criteria. A thorough screening of the studies for relevance to the research question resulted in 19 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 14 consensus statements and recommendations, 12 of which were given a strength of “A”, one of which was given a strength of “B”, and one of which was given a strength of “C”. Conclusion Bimekizumab results in rapid and long-lasting clinical improvement for patients with moderate to severe plaque psoriasis and psoriatic arthritis. It has demonstrated superior efficacy when compared to several other biologics. The safety profile is consistent with other biologics, except for an increased incidence of oropharyngeal candidiasis.

show abstract

A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab

Cited by 22 publications

References 9 publications

JAK Inhibitors in Psoriatic Disease

JAK Inhibitors in Psoriatic Disease

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Contact Info

Product

Resources

About